The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).
Condition: Peripheral T Cell Lymphoma Intervention: Drug: F520 Sponsor: Shandong New Time Pharmaceutical Co., LTD Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials